Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Cancer-related trials contact form
Phone: 855-776-0015 (toll-free)
International patient clinical studies questions
Tab Title Description
A group of Mayo Clinic Biobank participants were genotyped for genetic variants as part of a separate study and a subset were found to be carriers of one or more important variants that increased risk of severe (grade 3, 4 or 5) toxicity.
These variants were reviewed by experts at Mayo Clinic and judged to: 1) have important health implications (toxicity) for participants if they were ever exposed to pharmaceutical agents containing 5-fluoruracil, and 2) to be clinically actionable (change options for treatment).
The purpose of this study is to return results to participants enrolled in the Mayo Clinic Biobank (IRB 08-007049) who are known to carry genetic variants likely to cause toxicity if exposed to 5FU or capecitibine.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
Mayo Clinic principal investigator
Janet Olson, Ph.D.
Closed for enrollment
Jamison Odiet CRAT
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.